Mechanism explainer · Type 2 diabetes
Mounjaro (tirzepatide) is the first medication approved for type 2 diabetes that activates two incretin receptors at once: GIP and GLP-1. That dual action is why it produces larger HbA1c reductions than GLP-1-only drugs in head-to-head trials, and it is the reason Eli Lilly secured FDA approval (NDA 215866) in May 2022.
Below: how Mounjaro lowers blood sugar at the organ level, what the SURPASS trials actually showed in adults with type 2 diabetes, and how the same molecule stacks up against Ozempic in a head-to-head trial. For the broader brand overview, see what Mounjaro is and who it is approved for.
Key takeaways
- Dual receptor agonist: Mounjaro binds and activates both the GIP receptor and the GLP-1 receptor simultaneously, the first drug in its class for type 2 diabetes.
- GLP-1 effects: glucose-dependent insulin secretion, glucagon suppression, and slower gastric emptying lower post-meal blood sugar.
- GIP effects: a complementary incretin signal that amplifies insulin release and appears to improve insulin sensitivity.
- SURPASS-1 monotherapy result: HbA1c fell by 1.87 to 2.07 percentage points across dose arms vs placebo over 40 weeks, and up to 52 percent of participants on 15 mg reached HbA1c below 5.7 percent.
- Head-to-head: in SURPASS-2 (1,879 adults, 40 weeks), tirzepatide 15 mg cut HbA1c by 2.30 percentage points vs 1.86 for semaglutide 1 mg.
- Dosing: 2.5 mg starting dose titrating in 2.5 mg steps every 4 weeks up to 15 mg, once-weekly subcutaneous injection.
- Half-life: approximately 5 days; steady state in roughly 4 to 5 weeks of weekly dosing.
What Mounjaro is, and what makes it different
Mounjaro is Eli Lilly's brand name for tirzepatide, a once-weekly injectable peptide approved by the FDA in May 2022 under NDA 215866 for adults with type 2 diabetes. The same molecule is marketed as Zepbound for chronic weight management; the indications differ, the drug does not. For the brand-level breakdown, see how Mounjaro and Zepbound differ.
Mounjaro is a dual agonist, and that matters
A dual agonist binds and activates two distinct receptors at once. Mounjaro hits the GLP-1 receptor (the same target as Ozempic) and adds the GIP receptor on top of it. Eli Lilly coined the marketing term "twincretin" for this design. In the SURPASS-2 head-to-head T2D trial, the dual approach delivered larger HbA1c reductions than a GLP-1-only comparator at clinical doses.
15 mg, 40 weeks
NDA 215866
Plan Your Mounjaro Dosing Curve
See how tirzepatide builds in your system across the 2.5 to 15 mg titration, where steady state lands, and what each step costs in onset time.
Open the Tirzepatide CalculatorHow Mounjaro lowers blood sugar in type 2 diabetes
Quick Answer
Mounjaro lowers blood sugar by activating two hormone receptors: GLP-1 and GIP. GLP-1 receptor activation stimulates insulin release from the pancreas when blood sugar is elevated, suppresses glucagon, and slows gastric emptying. GIP receptor activation adds a complementary incretin effect, amplifying insulin secretion and supporting insulin sensitivity. Together, these actions lower HbA1c more effectively than GLP-1-only medications.
In type 2 diabetes the body still makes insulin but does not use it well, and the pancreas often releases too much glucagon (the hormone that tells the liver to pour glucose into the blood). Mounjaro pushes back on both ends of that imbalance and adds a third lever by slowing how fast food reaches the small intestine. The result is a flatter post-meal glucose curve and a lower HbA1c over time.
GLP-1 receptor activation: the insulin and appetite pathway
GLP-1 is an incretin hormone your gut releases after meals. When Mounjaro activates the GLP-1 receptor, three things happen at once:
- Glucose-dependent insulin secretion. Pancreatic beta cells release insulin, but only when blood sugar is elevated. That dependency is why hypoglycemia is uncommon with Mounjaro alone.
- Glucagon suppression. Alpha cells in the pancreas put out less glucagon, so the liver releases less glucose into circulation between meals.
- Slower gastric emptying. Food leaves the stomach more gradually, blunting the post-meal glucose spike and prolonging satiety.
This is the same receptor Ozempic targets. The mechanistic difference between the two drugs lives in what Mounjaro does beyond GLP-1, which the next section covers. For the full side-by-side, see Mounjaro vs Ozempic.
GIP receptor activation: the complementary incretin effect
GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. Native GIP signaling is blunted in type 2 diabetes, and historically researchers were skeptical that re-activating it would help. Tirzepatide's clinical data forced a rethink. In the T2D setting, GIP receptor activation appears to:
- Amplify glucose-dependent insulin secretion when paired with GLP-1 signaling.
- Support direct improvements in insulin sensitivity at fat and muscle tissue. Research estimates only about 20 percent of tirzepatide's insulin sensitivity gains are explained by weight loss alone.
- Modulate how the body partitions fat storage, though the precise human biology is still being worked out.
Honesty note: the GIP receptor's exact role in human fat tissue is not fully resolved. Researchers describe a coherent picture from animal work and human trial outcomes, but the mechanistic details are still being characterized. Anyone presenting GIP biology as settled is overselling the literature. The molecular pharmacology lives in how tirzepatide works at the molecular level.
Why dual agonism outperforms GLP-1 alone in T2D
SURPASS-2 ran tirzepatide head-to-head against semaglutide 1 mg in 1,879 adults with type 2 diabetes over 40 weeks. At the 15 mg dose, tirzepatide cut HbA1c by 2.30 percentage points versus 1.86 for semaglutide. On weight, the trial reports treatment differences rather than absolute percentages: tirzepatide 15 mg participants lost approximately 5.5 kg more than the semaglutide arm over the same period. Adding the GIP signal on top of GLP-1 produced measurably better glycemic outcomes in a population that was already responding to GLP-1.
What the SURPASS trials showed for type 2 diabetes
Mounjaro's FDA approval rests on the SURPASS program, a set of phase 3 trials in adults with type 2 diabetes. Note that SURPASS is the T2D program; the SURMOUNT trials (which produced the well-known 20.9 percent weight loss number) studied tirzepatide in obesity without diabetes, and that data does not support Mounjaro's label directly.
SURPASS-1: tirzepatide vs placebo as monotherapy
SURPASS-1 enrolled adults with type 2 diabetes managed on diet and exercise alone, with no other glucose-lowering medication on board. Over 40 weeks, all three tirzepatide dose arms produced large HbA1c reductions versus placebo:
| Dose arm | HbA1c reduction (40 weeks) | Reaching HbA1c < 5.7% |
|---|---|---|
| Tirzepatide 5 mg | -1.87 percentage points | Approximately one-third of participants |
| Tirzepatide 10 mg | -1.89 percentage points | Approximately 45 percent |
| Tirzepatide 15 mg | -2.07 percentage points | Up to 52 percent |
| Placebo | Essentially unchanged | Single-digit percent |
The 5.7 percent threshold is the upper bound of the non-diabetic range. Reaching it on monotherapy is a striking outcome and is the centerpiece of Mounjaro's clinical case. Source: Rosenstock et al., Diabetes Care, 2021.
SURPASS-2: tirzepatide vs semaglutide head-to-head
SURPASS-2 randomized 1,879 adults with type 2 diabetes (on background metformin) to one of three tirzepatide doses or semaglutide 1 mg once weekly, for 40 weeks. All three tirzepatide doses outperformed semaglutide on HbA1c:
| Treatment arm | HbA1c reduction (40 weeks) |
|---|---|
| Tirzepatide 5 mg | -2.01 percentage points |
| Tirzepatide 10 mg | -2.24 percentage points |
| Tirzepatide 15 mg | -2.30 percentage points |
| Semaglutide 1 mg | -1.86 percentage points |
Weight effects in SURPASS-2 are reported as treatment differences rather than absolute percent change per arm. Tirzepatide 15 mg participants lost roughly 5.5 kg more than the semaglutide group over the 40 weeks. Source: Frias et al., New England Journal of Medicine, 2021.
What about weight loss on Mounjaro?
Weight loss happens on Mounjaro, but as a secondary effect of treating type 2 diabetes. The widely cited 20.9 percent mean weight loss at 15 mg over 72 weeks comes from SURMOUNT-1, which studied tirzepatide in adults with obesity and without type 2 diabetes. That trial supports Zepbound's obesity approval, not Mounjaro's T2D approval. The two are the same molecule with different label scopes and different patient populations. Do not conflate them.
How Mounjaro is dosed and how it reaches full effect
The dose ladder: 2.5 mg to 15 mg over five months
Mounjaro starts at 2.5 mg weekly, a sub-therapeutic dose chosen to let the GI system adapt. The label-recommended titration moves up by 2.5 mg every 4 weeks:
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, every 4 weeks
Not every patient needs to reach 15 mg. Many hit their HbA1c target at 5 mg or 10 mg and stay there. The full clinical protocol, including how to handle slow responders and tolerability issues, lives in the complete Mounjaro dosing guide.
Half-life and steady state: when Mounjaro reaches full effect
Tirzepatide has a half-life of approximately 5 days. That long half-life exists because the molecule carries a C20 fatty diacid chain that locks it tightly to albumin in the bloodstream, slowing elimination. Steady state, the point where weekly injections and weekly clearance balance out, takes roughly 4 to 5 weeks of consistent dosing. The practical implication: a new dose does not deliver its full pharmacological effect on day one. Appetite and glycemic effects build over the first month at each step.
The KwikPen: how Mounjaro is administered
Mounjaro ships in a single-dose KwikPen autoinjector. Injection is subcutaneous, rotating between the abdomen, thigh, or upper arm. The injection itself takes seconds. The dose ladder, not the injection technique, is where most patient questions land.
Side effects: what the mechanism predicts
Most Mounjaro side effects are mechanistically predictable. Slowing gastric emptying causes nausea. Altered gut motility causes diarrhea or constipation. The pattern lines up with what you would expect from a drug that aggressively manipulates incretin signaling. Deeper management strategies live in the tirzepatide side effects guide.
GI effects: nausea, diarrhea, constipation
The most common side effects are nausea, diarrhea, constipation, and vomiting. They are mostly mild to moderate and dose-dependent, occurring most often during dose escalation. The 4-week titration schedule exists precisely to give the GI system time to adapt before the next step. Most patients see symptoms ease within a few weeks at a stable dose.
Thyroid warning: what to know
Boxed warning
Mounjaro carries a boxed warning for thyroid C-cell tumors based on rodent studies. The relevance to humans has not been established, but the FDA contraindicates Mounjaro in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Source: FDA Mounjaro Prescribing Information, NDA 215866.
Mounjaro vs Ozempic: why the mechanism matters
Ozempic (semaglutide) hits the GLP-1 receptor only. Mounjaro adds the GIP receptor on top of that same target. In SURPASS-2, the dual approach delivered meaningfully larger HbA1c reductions than semaglutide 1 mg at clinical doses. Neither drug is automatically the right choice for every patient, but the data clarifies the trade-off.
| Dimension | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Receptor targets | GLP-1 and GIP | GLP-1 only |
| SURPASS-2 HbA1c (max dose) | -2.30 percentage points (15 mg) | -1.86 percentage points (1 mg) |
| Half-life | ~5 days | ~7 days |
| Dose range | 2.5 to 15 mg weekly | 0.25 to 2 mg weekly |
| FDA approval (T2D) | 2022 | 2017 |
Cost, supply, and side effect comparisons sit in Mounjaro vs Ozempic head-to-head.
Watch: Mounjaro explained by a board-certified physician
Dr. Christopher McGowan (gastroenterology and obesity medicine) walks through Mounjaro's mechanism, dose ladder, and clinical context in a concise 7-minute overview.
Frequently asked questions
How does Mounjaro lower blood sugar?
Mounjaro activates GLP-1 and GIP receptors at the same time. GLP-1 activation drives glucose-dependent insulin release from the pancreas, suppresses glucagon, and slows gastric emptying. GIP activation adds a complementary incretin signal. In SURPASS-1, HbA1c fell by 1.87 to 2.07 percentage points across dose arms versus placebo over 40 weeks.
How is Mounjaro different from Ozempic?
Ozempic (semaglutide) hits the GLP-1 receptor alone. Mounjaro (tirzepatide) hits both GLP-1 and GIP. In SURPASS-2 head-to-head over 40 weeks in 1,879 adults with type 2 diabetes, tirzepatide 15 mg reduced HbA1c by 2.30 percentage points versus 1.86 for semaglutide 1 mg.
How long does it take Mounjaro to work?
Half-life is approximately 5 days, so steady state arrives after about 4 to 5 weeks of weekly dosing. Blood sugar reductions begin in the first weeks, but each new dose needs another 4 to 5 weeks to reach full effect. HbA1c improvements keep building over several months as the lab marker reflects three months of average glucose.
Does Mounjaro cause weight loss?
Yes, weight loss happens on Mounjaro as a secondary effect of T2D treatment. The widely cited 20.9 percent mean weight loss at 15 mg over 72 weeks comes from SURMOUNT-1, an obesity trial in adults without type 2 diabetes. That data backs Zepbound's obesity indication, not Mounjaro's T2D approval. The same molecule is involved, but the trial populations differ.
Does Mounjaro cause nausea?
Nausea is the most common side effect, and it comes directly from the mechanism. Slowing gastric emptying keeps food in the stomach longer, which can register as nausea, especially after large or fatty meals. The starting 2.5 mg dose and the 4-week titration interval exist to let the GI system adapt before the next step.
Can Mounjaro cause low blood sugar?
Mounjaro's insulin-stimulating effect is glucose-dependent, so the pancreas only releases extra insulin when blood sugar is elevated. That makes hypoglycemia unusual with Mounjaro alone. Risk rises when Mounjaro is combined with insulin or a sulfonylurea, and prescribers often adjust those medications when adding tirzepatide.
Is Mounjaro approved for weight loss?
Mounjaro is FDA-approved only for type 2 diabetes in adults. Eli Lilly markets the same molecule (tirzepatide) as Zepbound for chronic weight management. Some prescribers use Mounjaro off-label for weight loss, but the on-label use is T2D management alongside diet and exercise.
Do you lose belly fat with Mounjaro?
Mounjaro produces overall body weight reduction, which includes visceral (abdominal) fat, but it cannot selectively target the belly. The GIP component appears to influence fat distribution in ways researchers are still characterizing. Individual fat-loss patterns vary. Mounjaro is approved for type 2 diabetes, not cosmetic body recomposition.
What happens at steady state?
After roughly 4 to 5 weeks of once-weekly injections, tirzepatide blood levels stabilize. At steady state the medication's glucose-lowering and appetite effects are at their maximum for that dose. This is why each titration step uses the same 4-week interval: each new dose needs another 4 to 5 weeks to reach full effect.
What are the cons of Mounjaro?
The main drawbacks are GI side effects during titration (nausea, diarrhea, constipation, vomiting), the boxed warning for thyroid C-cell tumors with contraindications for personal or family history of medullary thyroid carcinoma or MEN2, cost and intermittent supply pressure, and the reality that stopping treatment often reverses much of the metabolic benefit. The full side effect profile lives in the side effects guide.
Track Your Mounjaro Schedule with GLP3Planner
Our free pharmacokinetic calculator models how Mounjaro builds in your system, when each dose hits steady state, and what the titration schedule looks like on a week-by-week chart.
Open the Tirzepatide CalculatorReferences
- Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use. Prescribing Information. NDA 215866. Indianapolis, IN: Eli Lilly; 2022. [FDA label PDF]
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomized, Phase 3 Trial. Diabetes Care. 2021;44(12):2819-2831. doi:10.2337/dc21-1901. [PubMed]
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. [PubMed]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. [PubMed]
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009. [PubMed]
Medical disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Mounjaro is a prescription medication with a boxed warning for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Do not start, stop, or modify any medication regimen without consulting a qualified healthcare provider. Individual results vary. Discuss treatment options, risks, benefits, and alternatives with your doctor.
Related Mounjaro and tirzepatide articles
What Is Mounjaro?
Brand overview, indication, KwikPen, and the SURPASS approval story.
Complete Tirzepatide Dosing Guide
Full titration protocol from 2.5 mg to 15 mg with timing and tolerability guidance.
Tirzepatide Side Effects
What to expect at each dose and how to manage GI symptoms during titration.
Mounjaro vs Zepbound
Same molecule, different labels: T2D vs chronic weight management.
Ozempic vs Mounjaro
Head-to-head T2D comparison anchored on SURPASS-2 data.
How Does Tirzepatide Work?
Molecule-level pharmacology with the SURMOUNT-1 obesity context.